ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1387

Should Systemic Sclerosis Patients with Low Bicarbonate Have Replacement to Prevent Renal Dysfunction?

Megan Meier1, Jacob Stever2, Josephine Wright1, Tracy Frech3, Greg Stoddard1 and Benjamin Tingey1, 1University of Utah, Salt Lake City, 2University of Utah, SANDY, 3University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT

Meeting: ACR Convergence 2020

Keywords: Renal, Scleroderma, Systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: Systemic Sclerosis & Related Disorders – Clinical Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Scleroderma renal crisis (SRC) is a well-characterized condition in patients with systemic sclerosis, but systemic sclerosis patients frequently develop chronic kidney disease (CKD) without prior evidence of SRC. Retrospective analyses have shown that low serum bicarbonate predicts kidney failure and death in the general population. This study investigates the potential association of low serum bicarbonate levels (< 22 mmol/L) and the development of reduced kidney function in patients with SSc.

Methods: This was a retrospective cohort study comprised of patients with limited or systemic sclerosis (SSc) by 2013 ACR/EULAR criteria. Patients were recruited for participation from the University of Utah SSc Clinic from October, 2012 to March, 2017. Index and follow up bicarbonate levels and associated eGFR values were recorded. A serum bicarbonate level < 22 mmol/L and an eGFR < 60 ml/min/1.73m2 were considered low values for the purposes of this study. Patients with normal versus low serum bicarbonate levels at index date were followed and compared longitudinally during the study period for the development of kidney dysfunction, manifested by low eGFR. A zero-inflated Poisson (ZIP) regressions model was applied to estimate the rate of predicted low eGFR labs associated with low serum bicarbonate occurrences per patient.

Results: 143 patients met inclusion requirements for evaluation and had normal kidney function determined by eGFR at index date. In this SSc cohort, with each one count increase in low serum-bicarbonate labs, the rate of low eGFR labs increased (aIRR: 1.21; 95% CI: 1.05-1.40). This was a significant increase with P=0.01.

Conclusion: In a single center SSc cohort, low serial serum bicarbonate was associated with increased rates of reduced kidney function. Awareness of this association provides a means to screen for higher risk SSc patients and potentially intervene, given the reduction in morbidity and mortality seen with bicarbonate supplementation in patients with CKD in the general population.

The rate of predicted low eGFR occurrences, with error bars, plotted against the count of low serum-bicarbonate occurrences per patient .


Disclosure: M. Meier, None; J. Stever, None; J. Wright, None; T. Frech, None; G. Stoddard, None; B. Tingey, None.

To cite this abstract in AMA style:

Meier M, Stever J, Wright J, Frech T, Stoddard G, Tingey B. Should Systemic Sclerosis Patients with Low Bicarbonate Have Replacement to Prevent Renal Dysfunction? [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/should-systemic-sclerosis-patients-with-low-bicarbonate-have-replacement-to-prevent-renal-dysfunction/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/should-systemic-sclerosis-patients-with-low-bicarbonate-have-replacement-to-prevent-renal-dysfunction/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology